---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106243"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:31:00.268627+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# 4DMT Q2 net loss $54.7M; accelerates 4D-150 Phase 3 wet AMD data to H1 2027

## Summary
- Cash $417M (down from $505M Dec 2024); funds into 2028; workforce cut ~25% saves ~$15M/yr.
- Net loss $54.7M vs $35.0M Q2 2024; R&D spend $48.0M (+50% YoY) on Phase 3 startup.
- 4FRONT-1 wet AMD Phase 3 topline data accelerated to H1 2027; 4FRONT-2 initiated ahead of schedule.
- DME SPECTRA 60-wk: Phase 3 dose 78% fewer injections vs on-label aflibercept; FDA/EMA align on single-study approval.
- RMAT designation for 4D-150 in DME; 4D-710 cystic fibrosis cohort enrollment complete, data Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-106243
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017025106243/0000950170-25-106243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017025106243/fdmt-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106243
- JSON: https://secwatch.observer/filing/0000950170-25-106243.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106243.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.